9 recruiting, 3 not yet recruiting, 3 unknown. 9 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 6, Not yet recruiting 2, Unknown 1 |
| Phase 1 | 5 | Unknown 3, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 4 | Recruiting 3, Not yet recruiting 1 |
Follow 9MW2821: new trials by email Literature Review of 9MW2821 trials Research Report on 9MW2821
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer 9MW2821, Chemotherapy - Locally Advanced or Metastatic Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 356 | 2026-05-01 | 2026-04-30 |
| NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | Peking University Third Hospital | 40 | 2026-02-01 | 2026-02-17 |
| 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer 9MW2821, Toripalimab Injection - Urothelial Carcinoma | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 90 | 2025-08-01 | 2026-01-02 |
| A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors 9MW2821, Other anti-cancer therapy - Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 188 | 2025-04-01 | 2025-04-27 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma 9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 60 | 2025-01-17 | 2025-03-21 |
| Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer SHR-A1811, SHR-A1921, SHR-A2009 - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Fudan University | 160 | 2024-10-21 | 2026-09-03 |
| A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer 9MW2821, Chemotherapy - Cervical Cancer | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 420 | 2024-09-10 | 2024-11-22 |
| 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab, Gemcitabine - Urothelial Carcinoma | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 460 | 2024-08-22 | 2024-09-19 |
| A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer 9MW2821, PD-1 inhibitior - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 160 | 2024-07-26 | 2025-01-10 |
| Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) 9MW2821 - Bladder Cancer | Phase 1 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2024-04-22 | 2024-08-13 |
| A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer 9MW2821, Chemotherapy - Advanced Urothelial Carcinoma | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 432 | 2023-12-29 | 2025-04-13 |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer 9MW2821, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 100 | 2023-09-27 | 2024-09-19 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
| A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors 9MW2821 - Advanced Malignant Solid Tumors | Phase 1 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 40 | 2022-06-21 | 2024-09-19 |
| A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors 9MW2821 - Solid Tumors | Phase 1 / Phase 2 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 208 | 2022-06-11 | 2022-06-15 |
Triple Negative Breast Neoplasms (4) · Carcinoma, Transitional Cell (3) · Breast Neoplasms (2) · Genital Neoplasms, Female (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Complete Response (1) · Urinary Bladder Neoplasms (1) · Urogenital Neoplasms (1) · Uterine Cervical Diseases (1) · Uterine Cervical Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
Mabwell (Shanghai) Bioscience Co., Ltd. (11) · Fudan University (2) · Peking University Third Hospital (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)
China (15)
Feng Wang (1) · Zhimin Shao, M.D. (1) · Zhimin Shao, Professor (1)